FLT3 and acute myeloid leukemia: The combination of CPX-351 + FLT3 inhibitors for AML will be further investigated in the phase I/II NCT04128748 study (CPX-351 + quizartinib), the phase I/II NCT04982354 study (CPX-351 + midostaurin), and the phase III NCT04293562 study (CPX-351 + gilteritinib), which are currently recruiting patients.